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1. Introduction
Helicobacter pylori (H pylori) is a spiral-shaped bacterium that is attached to or just above the
gastric mucosa. The organism can persist in the stomach indefinitely and may not cause clinical
illness for many years after infection [1]. Indeed, a large number of infected patients never
develop any symptoms [2, 3]. However, literature has also associated H pylori infection with
gastritis and gastric malignancies (gastric adenocarcinoma and MALT-lymphoma) [4].
Chronic H pylori infection has also been associated with several extra intestinal diseases, such
as autoimmune thrombocytopenia, sideropenic anemia and chronic urticaria but the patho‐
genesis is still not known [5]. H pylori gastric infection is one of the most prevalent infectious
diseases worldwide with an estimate of 40%-50% of the world population [3]. Remarkable
differences are due to geographical, socio-economic and demographic factors [6]. H pylori
transmission is still not completely understood. In addition, among infected patients, the
reasons why only some develop symptoms is still a matter of speculations. Studies suggested
that H.pylori is also transmitted from domestic animals like cat and sheep, but humans are the
primary reservoir of H pylori infection [7, 8]. Several tests are available to detect H pylori in
patients with ulcer or dyspepsia. The more commonly used tests are the evaluation of biopsy
specimens during upper gastrointestinal tract (GI)I endoscopy, the detection of serum anti H
pylori antibodies and breath tests with 13C-labeled urea (9-11) The discovery that most upper
gastrointestinal diseases are the consequence of H pylori infection that can be treated with
antibacterials, is an important medical advance [12]. Although, in the last few decades, H
pylori eradication has been standardized, occurrence of resistance to therapeutic regimens is a
growing problem [3, 14]. The purpose of this paper is to provide an appraisal of the most
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effective, current treatments available for H pylori, and to speculate on the potential for newer
approaches in treatment and prophylaxis in future.
2. Epidemiology and prevalence
Humans are the only host for H.pylori, which is found in stomach, duodenum, esophagus
and rectum on areas of metaplastic gastric epithelium [15]. Other H.pylori species have been
isolated from the animals [16].  Animal models of Helicobacter  infection have been devel‐
oped due to shared characteristics of other H.pylori like H.mustelae and H. felis with H.pylori.
H.pylori exists the world over and its prevalence in the population increases with age [17,
18] In developed countries, prevalence increases with rate of 1% per year of age, where as
it  is  rare  in  children,  and reaches  70% in  the  seventh decade [19].  In  developing coun‐
tries, more than 50% children acquire the infection by the age of 10 years, and more than
80%  of  the  population  gets  infected  by  the  age  of  20  years  [20-22].  In  asymptomatic
individuals prevalence of H.pylori infection varies from 31%-84% [22]. H.pylori infection is
chronic and once acquired remains life long, unless eradicated by antibiotics given for some
other  conditions  [22].  Humoral  and tissue  immune response  by  the  host  is  usually  not
sufficient to clear the infection. Though the mode of transmission is not yet well establish‐
ed, most probably it occurs by oral-oral or faeco-oral route and important risk factors are
socioeconomic status and age [7, 8]. Overcrowding, poor socio-economic status and poor
hygiene are associated with high infection rate. Re-infection rate after eradication is quite
high in developing countries due to above mentioned risk factors [23].
Colonization of H.Pylori occurs by producing urease and gastric acid inhibitory protein. It
can colonize only in gastric type epithelium and cannot stay anywhere else in the GI in the
absence of gastric mucosa [24]. Metaplasia, which is present in more than 90% of patients
of duodenal ulcer, occurs by replacing the columnar cells, normally covering the duode‐
nal villi, by gastric type epithelium. Adhesion of H.pylori to the gastric epithelium occurs
by tissue specific proteins. Colonization of the duodenal bulb by H.pylori leads to mucos‐
al inflammation which makes it vulnerable to attack by acid or pepsin or bile resulting into
ulceration,  however,  factors  leading  to  gastric  metaplasia  in  the  duodenal  bulb  are  not
known. Stimulation of the immune system of H.pylori  contributes to host damage and it
evades the immunological clearance [25-2]).
3. Diseases associated with H.pylori
H.pylori infection is found to be associated with gastritis, non-ulcer dyspepsia (NUD), duode‐
nal ulcer, gastric ulcer, gastric cancer, gastric lymphoma of mucosa associated lymphoid tissue
(MALT) and even coronary heart disease [28, 29]. It has now been well established that H.pylori
is the cause of almost all duodenal ulcers (DU) and chronic benign gastric ulcers (GU) which
are not associated with nonsteroidal anti-inflammatory drugs (NSAID) [30]. More than 95%
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of DU and 90% of GU are associated with H.pylori infection and there is a dramatic decrease
in their relapse rate after the H.pylori eradication. Right now there is no convincing evidence
that NUD symptoms are due to H.pylori infection. Prevalence of H.pylori infection is compa‐
rable between healthy individuals and patients with the symptoms of NUD. Recurrent
abdominal pain in children suggestive of NUD subsides after the eradication of H.pylori which
indirectly associates H.pylori infection with NUD. However, further studies are necessary to
eradicate H.pylori completely in NUD. [31]
4. Current therapy of H.pylori infection
The objective of H. pylori treatment is the complete elimination of the organism from the GI of
patients and once this has been achieved then the rate of reinfection is low. Development of a
successful treatment for H. pylori infection has been fraught with difficulty. The survival
capabilities of the H.pylori organism over a wide pH spectrum within the stomach make the
task of eradication difficult [32]. The organism must be eradicated from each of these potential
niches and this is a daunting task for any single antibiotic. Initial attempts to cure the infection
showed that the presence of antibiotic susceptibility in vitro did not necessarily correlate with
successful treatment. It was rapidly recognized that the therapy with a single antibiotic led to
a poor cure rate and various antimicrobial mixtures were tried resulting in several effective
combinations of antibiotics, bismuth and antisecretory drugs [33, 34].
It is vital that the infection be treated optimally with clinically relevant H.pylori– eradica‐
tion regimens that has an acceptably high eradication rate and without major side effects
and with minimal induction of bacterial resistance. The reasonable eradication targets would
be ≥90% cure rate on per-protocol analysis, and ≥80% cure rate on intent-to-treat analysis
[35]. Such goals have not been achieved with antibiotics alone. Because of luminal acidity
influences the effectiveness of some antimicrobial agents that are active against H. pylori.
In order to achieve the desirable eradication rate, the antibiotics are combined with proton-
pump inhibitors or ranitidine bismuth citrate.  So-called triple therapies,  combinations of
one  anti  secretory  agent  with  two  antimicrobial  agents  for  7  to  14  days,  have  been
extensively evaluated, and several regimens have been approved by the Food and Drug
Administration (FDA). Combination drug regimens are essential to maximize the chance
of  eradicating  the  infection  and  to  minimize  the  risk  of  promoting  antimicrobial  (to
metronidazole and clarithromycin) resistance [35].
The most widely used antimicrobials in these regimens are amoxicillin, clarithromycin,
metronidazole, tetracycline, and bismuth. Resistance of H pylori to the limited range of
antibiotics that have efficacy in its treatment can severely affect attempts to eradicate the
bacteria. Resistance to tetracycline or amoxicillin is extremely rare [36, 37]. The issue of
resistance primarily concerns the nitroimidazoles (metronidazole or tinidazole) and macro‐
lides (clarithromycin) [38, 39]. Prevalence of H pylori resistance to metronidazole is approxi‐
mately 25% in developing countries, because of the frequent use of nitroimidazoles to treat
other diseases% [40, 41]. Increasing the dosage of metronidazole administered (e.g., from 1.0
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to 1.5 g/day) generally improves the results of therapy when treating metronidazole-resistant
H.pylori strains. Resistance to clarithromycin is becoming more prevalent in some European
countries, where the prevalence may be as high as 17% [40, 41]. The clinical effect of clarithro‐
mycin resistance is essentially complete loss of any clarithromycin anti-H pylori effect; outcome
of therapy can generally be predicted on the basis of what could be expected if only the other
antimicrobials in the regimen are used [39].
4.1. First-line therapy of H.pylori infection
First-line H. pylori therapy should ideally be short, easy to administer, well tolerated and
relatively cheap [42]. However, over and above these considerations, the prime objective of
any treatment is to eradicate the infection in the maximum number of patients [43]. Some of
the best validated first-line treatments for H pylori include amoxicillin or clarithromycin-based
triple therapies, which consists of a proton pump inhibitor PPI (standard dose twice daily)
combined with clarithromycin (500 mg twice daily) and either amoxicillin (1 g twice daily) or
metronidazole (500 mg twice daily) for a minimum of 7 days. Bismuth-based quadruple
therapies consisting of a histamine receptor antagonist or PPI combined with bismuth,
tetracycline, and metronidazole [42, 43]. Another alternative approach is to include ranitidine
bismuth citrate (RBC) in place of a PPI in clarithromycin triple therapy. These regimens have
the propensity to eradicate 70 to 85% of the infection. However, the regimen, which employs
a PPI with clarithromycin and amoxicillin is the most widely endorsed first-line regimen for
H pylori [42, 43]. Any of the currently available PPIs may be used with equivalent treatment
efficacy [44, 45] with the exception of esomeprazole as it is prescribed once daily because it is
imperative that the standard dose of a PPI be prescribed twice daily in order to maximize
treatment efficacy [46]. RBC is sometimes used in place of a PPI in countries outside the United
States with at least equal and perhaps greater efficacy [47]. Metronidazole can be used as an
alternative to amoxicillin, particularly in the setting of penicillin allergy or intolerance [42, 43].
Bismuth-based quadruple therapy is another option in penicillin allergic patients which yields
similar eradication rates to clarithromycin triple therapies [48, 49]. A recent meta-analysis
including five randomized trials reported intention-to-treat (ITT) and per protocol (PP)
eradication rates of 79% and 85% for clarithromycin triple therapy and 80% and 87% for
bismuth quadruple therapy, respectively [50]. Recently, simplified twice-daily dosing regi‐
mens for bismuth quadruple therapy have been successfully used in clinical trials [51].It is
worth noting that the dosing of metronidazole used in the various bismuth quadruple
therapies has not been consistent across studies. As higher doses of metronidazole (500 mg)
may provide better cure rates than lower doses (250 mg), caution must be exercised when
interpreting the data from comparative studies and pooled analyses involving quadruple
therapies. Although there is no universal standard, there has been a desire to decrease the
duration of therapy, particularly in countries outside the United States where treatment
durations of at least 7 days have been recommended [42]. Until very recently, the recom‐
mended treatment duration in the United States has been 10–14 days due to lower eradication
rates with 7-day regimens [52]. However, a large randomized US trial, rabeprazole-based triple
therapy for 7 days was found to be as effective as 10 days of therapy (ITT eradication rates of
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77% [ 71%–83%] vs. 78% [ 72%–84%], respectively) [53]. Based upon these results, 7-day
rabeprazole-based triple therapy has been approved by the Food and Drug Administration
for use in the United States. However there is some minor disagreement on the duration of
treatment; the US guidelines recommend a 14-day course, whereas in Europe, a 7-day course
is considered to be sufficient and Canadian and Asia–Pacific guidelines correspond largely to
the Maastricht 2–2000 guidelines [54].
4.2. Second-line therapy of H.pylori infection
The choice of second-line treatment depends on which treatment approach was used initially,
because retreatment with the same regimen is not recommended. If a clarithromycin-based
regimen was used initially, a metronidazole-based regimen should be used as follow-up (in
combination with a PPI, tetracycline, and bismuth), and vice versa. Prolonging the treatment
period to 14 days is probably necessary. Because bacterial resistance to metronidazole or
clarithromycin results primarily from previous treatment failures, first-choice treatment
should never combine clarithromycin and metronidazole in the same regimen [55]. Second-
line therapy has been extensively reviewed by several authors [55-57]. The assessment of H
pylori sensitivity to antibiotics may be useful only after failure of the second-line therapy [58]
The most widely recommended second-line treatment for persistent H pylori infection is
quadruple therapy with a PPI (standard dose twice daily), bismuth salt (subsalicylate or
subcitrate 120 mg 4 times daily), metronidazole (500 mg thrice daily) and tetracycline (500 mg
4 times daily) for minimum of 7 days. Further failures should be managed by specialists. The
Table 1 summarizes the suggested therapeutic regimens for eradication of H pylori infection.
No other second-line treatment strategies have been widely endorsed; however, -line therapy
should be [59] rifabutin-based triple therapy and furazolidone-based triple therapy [59, 60]
have been investigated and suggested as alternatives to bismuth quadruple therapy (Table
1). As second-line therapy, the Maastricht 2-2000 Consensus Report suggests a quadruple
therapy based on bismuth (120 mg, q.i.d.), tetracycline (500 mg, q.i.d.), metronidazole (500 mg,
t.i.d.) and antisecretive agent (PPI, b.i.d.) for a minimum of 7 days [34]. Further trials have
shown that replacing the proton pump inhibitor and the bismuth compound of the quadruple
therapy by RBC also achieves good results, with an eradication rate ranging between 57%-95%
[61, 62]. The failure of second line quadruple therapy is associated with its discontinuation
because of high incidence of side effects (6%-68%) [63]. A triple therapy with the combination
of levofloxacin, rabeprazole and tinidazole or amoxicillin has been proposed as an alternative
to Maastricht. This protocol shows an eradication rate higher than 90% compared to quadruple
therapies given for 7 days (63%) with a lower incidence of side effects [64]. Rifabutin has been
shown to have a good eradication rate (87%), if administered at a high dose (300 mg) in
combination with amoxicillin and PPI, as compared to quadruple therapy. Wong et al [65]
showed that a combination of levofloxacin, rifabutin and rabeprazole has a high efficacy with
an eradication rate >90%. Furazolidone is also used to replace metronidazole in quadruple
therapy [66]. Different in vivo studies have confirmed the efficacy of regimens containing a
high-dose furazolidone [200 mg, b.i.d.] as the second-line therapy in patients with metroni‐
dazole-resistance [66]. Many other combinations have been used with various rates of success.
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Bacterial eradication may fail in up to 40% of cases after the suggested second-line regimens.
As a consequence, to treat patients who have already undergone the first- and second-line
therapies is a common challenge [67]. A recent rifabutin based triple therapy shown eradication
rates of 100 and 87.5 % (Per Protocol and Intention-to-Treat analysis) in primary resistance to
clarithromycin and tinidazole and 82.2 and 78.5% in secondary resistance [68].
4.3. Third-line rescue therapy for persistent H.pylori infection
Patients who fail both first- and second-line therapy are a clinical challenge. New modified
eradication regimes involve the substitution of antibiotics used with other drugs, such as
rifabutin, levofloxacin, and furazolidone [58-65] These antibiotics should be considered for
third-line treatment. Currently, no widely endorsed treatment regimens are available, for
persons with persistent H.pylori infection despite two or more previous courses of antibiotics
(third-line therapy). A number of third-line regimens such as bismuth quadruple therapy,
rifabutin-based triple therapy, levofloxacin-based triple therapy furazolidone-based triple
therapy and Doxycycline-based therapy have been investigated and shown in Table 2.
The new fluoroquinolone, levofloxacin, has shown an excellent activity against a variety of
Gram-positive and Gram-negative organisms which are resistant to the established agents
Matsuzaki et al [69] studied several strains and reported that levofloxacin had an excellent and
wide spectrum antibacterial activity compared with other fluoroquinolones and antibiotics
tested [69]. A previous study has shown efficacy and safety of levofloxacin based triple therapy
in H.pylori infection first-line therapy [70]. Recently, Gatta et.al [71] have proposed a third-line
treatment after two eradication failed courses without fluoroquinolones, with standard dose
of PPIs (b.i.d.), levofloxacin (250 mg, b.i.d.) and amoxicillin (1 g, b.i.d.) for 10 days. The
eradications rates of 76.2% and 84.6% according to ITT and PP anlysis, respectively, have been
achieved. The levofloxacin-based treatment could eradicate most of the strains (92.3%) which
are resistant in vitro to both clarithromycin and metronidazole, but susceptible to levofloxacin.
Furthermore, this drug combination, successfully employed as rescue therapy, is well tolerated
and has no major side-effects [72].
Rifabutin, a spiropiperidyl derivative of rifamycin, has been shown to exhibit high in vitro
activity against H.pylori [73, 74]. Furthermore, clinical trials have suggested that rifabutin may
be a possible candidate for second or third line eradication combination therapy [75]. Further‐
more, rifabutin is chemically stable at a wide pH range [74]. Recently, rifabutin-based rescue
therapies (twice-daily standard-dose PPI plus amoxicillin 1 g twice daily or levofloxacin 500
mg once daily plus rifabutin 300 mg daily, for 7 days) have been shown to represent an
encouraging strategy for eradication failures because they are effective against H pylori strains
resistant to clarithromycin or metronidazole [75, 76]. However, rifabutin is very costly, and
concerns still remain about the widespread use of this drug because of the possibility for
accelerating development of drug resistance. Results of a recent study [59] suggest that a 10-
day rescue therapy regimen based on the use of rabeprazole (20 mg twice daily) plus amoxi‐
cillin (1 g twice daily) plus levofloxacin (500 mg once daily) is more effective than standard
quadruple regimen as a second-line option for H.pylori eradication. Additionally, a 7-day
quadruple-therapy regimen containing amoxicillin and tetracycline has recently been proven
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more effective than standard quadruple therapy with metronidazole and tetracycline to rescue
failed triple therapy, by overcoming the antimicrobial resistance of H.pylori [77-81].
Doxycycline is a widely used tetracycline antibiotic for eradicating several infections. With
respect to tetracycline, Doxycycline requires the administration of only two tablets per day,
leading to a better compliance in patients undergoing eradication therapies. Furthermore,
Heep et.al [82] have found no secondary resistance to doxycycline in H.pylori patients who
failed one or more eradication therapies. Quadruple regimens represent the most widely used
rescue therapy. Induction of metronidazole resistance has suggested a new protocol, namely
replacing tetracycline with doxycycline (because it requires the administration of only two
tablets per day) and metronidazole with amoxicillin (because its resistance is less 1%), one
week quadruple therapy with doxycycline (100 mg, b.i.d.), amoxicillin (1 g, b.i.d.), omeprazole
(20 mg, b.i.d.) and bismuth salts (120 mg, two tablets b.i.d). This treatment has proved to be a
highly effective third-line ‘rescue’ therapy, achieving 91% eradication rate in patients har‐
bouring metronidazole and clarithromycin resistant H pylori strains (by ITT analysis) [83].
This regimen shows excellent compliance (99%) with mild side-effects.
1.
Bismuth subsalicylate (120 mg q.i.d ) + metronidazole (500 mg t.i.d) + tetracycline (.500 mg q.i.d ) + proton pump
inhibitor
( standard dose b.i.d) for a minimum of 7 days
2. Levofloxacin (250 mg b.i.d) + amoxicillin (1g mg b.i.d) + proton pump inhibitor ( standard dose b.i.d) for 10 days
o.d = once daily; b.i.d = twice daily; t.i.d = three times daily; q.i.d = four times daily
Table 1. Second line therapy regimens of H.pylori infection.
1 Rifabutin (300 mg o.d ) + amoxicillin (1g b.i.d )+ proton pump inhibitor ( standard dose b.i.d) for 10 days
2 Furazolidone 200 mg bid + amoxicillin (1g b.i.d) + proton pump inhibitor ( standard dose b.i.d) for 14 days
3 Furazolidone 200 mg bid + tetracycline ( 1g b.i.d) + proton pump inhibitor ( standard dose b.i.d)+ bismuth (140mg b.i.d) for 7 days
4 Doxycycline (100 mg, b.i.d.) + amoxicillin (1g b..id) + omeprazole (20 mg, b.i.d)+ bismuth salts (120 mg, b.i.d) for7 days.
o.d = once daily; b.i.d = twice daily; t.i.d = three times daily; q.i.d = four times daily
Table 2. Third line rescue therapy regimens of H.pylori infection.
4.4. Failure of therapy
The reasons behind failure of these antibacterial treatments are not very clear, but are likely
multifactorial [85-87]. Failure of therapy is most frequently associated with drug resistance
and non-compliance, due to complexity of rgimens and associated side effects, e.g., nausea,
diarrhea, taste disturbances, mucositis, and pseudo membranous colitis. The continuing
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emergence of resistance to the conventional antibacterials used to treat H. pylori infections is
of major concern [85]. Resistance to nitroimidazoles (e.g. metronidazole) is extremely high in
the developing world and rates of resistance( >50%) have been described in Western countries
[39-41]. Strains of H. pylori which are resistant to clarithromycin are also now widespread e.g.,
10–17% in most part of Europe [39].
5. Future therapeutic strategies
Resistance in H. pylori is anticipated to increase because the currently effective drugs are used
to treat many other infections where also develops the drug resistance in body. So there is an
urgent need for improvement over current regimens due high resistance over no of antibiotics
using in current therapy and moreover current triple and quadruple therapies are may not be
desirable for widespread eradication of H. pylori infection in future. The next generation of
H.pylori therapeutic regimens should be simpler, novel and specific. There are some novel
approaches available to achieve this goal, such as development of therapeutic vaccine,
geonome bsed drug discovery, pathogen –host tissue adhesion inhibitor, and novel site specific
drug delivery at specific site of H.pylori infection.
5.1. Vaccine development
The success of eradication of H.pylori by antibiotic therapy is being hampered by the increasing
occurrence of antibiotic resistance H.pylori strains and patience compliance. Consequently
investigative attention has been focused on development of an effective therapeutic vaccine.
From mathematical [88] and animal models [89] of H. pylori colonization, the host response
has been suggested to play an important role in bacterial growth regulation. Immunization
against H. pylori may thus be considered as a strategy to deviate the immune response
programmed by infection, i.e., the re-direction of a host response from natural infection leading
to persistence of infection and gastric disease, to another state in the host response capable of
attenuating or eliminating H. pylori and its associated gastric inflammatory sequelae. Evidence
from both animal models and humans implicate H. pylori in the activation of B cell and T cell
functions leading to heterogeneous systemic and local antibody responses, lymphoid follicle
hyperplasia, and significant recruitment of CD4+and CD8+ T cells [90, 91].
Vaccination against H. pylori has been performed in several animal models. Although several
studies showed the benefit of prophylactic as well as therapeutic vaccination in animals,
bacterial eradication was not observed in humans [92]. Knockout studies in mice revealed that
the Th2 response can be absent but immunization is still possible when using urease as an
antigen [93, 94].
A number of novel approaches to delivery of H. pylori vaccine have been reported recently.
Smythies et.al [95] reported on H.pylori vaccination based on a modified polio virus vector
where the capsid genes are replaced with H.pylori urease B. Poliovirus UreB replicons were
co-administered with a recombinant vaccinia virus engineered to express polio virus capsid
proteins, resulting in a vaccine which can only undergo one round of infection. Mice which
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are transgenic for the human poliovirus receptor (C57BL/ 6/DAB) are susceptible to infection
with poliovirus via the systemic route. Replicon vaccination resulted in clearance of an
established H.pylori infection in 73% of mice compared to 31% of vector-immunized controls.
Furthermore, immunization prevented an infection from becoming established in 80% of
immunized mice. Bacterial ghosts (Gram-negative bacterial cell envelopes, devoid of cyto‐
plasmic envelopes) have also been shown to have good adjuvant properties [96]. H. pylori
ghosts induced protection in a mouse model without the use of an additional adjuvant,
although batch-to-batch variations were observed and improvements are therefore required
before this approach could have practical applications [97]. Sodium alginate microbeads have
also been tested for controlled release of a model H. pylori vaccine [98]. Alginate beads are
widely used for encapsulation of drugs, and the mild formulation conditions, and their
reported muco-adhesive properties should make them ideal carriers for vaccine antigens.
Recombinant urease encapsulated in alginate beads was administered to mice via the subcu‐
taneous, nasal and oral routes. Unexpectedly, only subcutaneous delivery induced a signifi‐
cant antibody response and led to reductions in H. pylori colonization (as determined by urease
test) indicating that this approach also needs further improvement [98].
DNA vaccines are a potentially attractive approach to vaccination, and a genomic library
approach has shown encouraging preliminary results in mice [99]. Two recent studies have
investigated the adjuvant properties of CpG motifs in the context of DNA immunization.
Interestingly, a prototype immunization construct encoding the UreB subunit which included
CpG motifs [100] induced significant increases in the expression of IL-10 and beta-defensins
in the gastric mucosa. In an approach that aimed to induce and modulate the immune response
by triggering a specific Toll-like receptor (TLR), Sommer et.al [101] immunized C57BL/6 mice
with H. pylori lysate mixed with a synthetic CpG oligonucleotide targeted at TLR-9 (CpG
oligonucleotide 1688). Immunization induced a Th1-biased immune response as expected, and
immunized mice had 10-fold reduced levels of H.pylori in the gastric mucosa after challenge.
Synthetic CpGs have recently been approved for human use as a therapy for genital warts
[102], and so given the encouraging results from mice, this approach might also be applicable
for a human H.pylori vaccine. However, DNA vaccination studies in human volunteers have
reported only suboptimal immune responses [103] and it appears that the barriers to DNA
uptake may be more difficult to overcome in humans [104]. To return to our original question
regarding what we have learned from the mouse model, the data from animal models of H.
pylori infection support the feasibility of both therapeutic and prophylactic vaccination, for
neonates and adults. Furthermore, a variety of routes of application and adjuvants are
effective. It is, however, clear that only a better understanding of the underlying immune
mechanisms will make it possible to improve efficacy and to address the issue of post immu‐
nization gastritis.
5.2. Genome-based drug discovery
The recent availability of the genome sequences of two different isolates of H.pylori [105, 106]
has provided much stimulus to research aimed at discovering and developing novel thera‐
peutics to eradicate H. pylori. H pylori is a relatively simple organism with a small genome of
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circa 1.7 × 106 nucleotides, varying slightly according to the strain of the organism, and encoding
around 1600 genes [107]. Of these, depending on the stringency of the comparison, roughly
55% have homologs of putative known identity in other organisms, while another 10% have
database homologs of unknown identity. The remaining 35% are unique to H pylori at this time.
This complement of 1600-1700 gene contain a relatively small number which encode proteins
whose functions are essential to the viability of the bacterium. A genome-based strategy
facilitates the expeditious advanced selection of novel lethal targets not used by current
antimicrobials, thus providing the opportunity to identify novel classes of antibacterials. In
the case of vaccine discovery and development, comparison of two genomes has allowed the
identification of a “common set” of H.pylori genes, among which genes encode antigens [108].
The principle underlying genome based drug development is to identify those essential
proteins which are specific to H.pylori, and then to isolate, identify and synthesize a small
molecule chemical which inhibits the essential activity of such proteins [105]. This approach
is designed both to identify a drug that will work as a monotherapy, which would be specific
for H pylori and would not interfere with other organisms. In case of H. pylori drug discovery,
the task is to identify those essential proteins which are specific for and conserved in H.
pylori. Identification of essentiality involves a process whereby attempts are made to mutate a
gene performed using an allelic recombination method via homologous recombination and
so” knock-out” its function [106]. If a particular mutant can be generated, the disrupted gene
does not code for a biological process that is required for viability in vitro. “Knock-out”
mutagenesis experiments with selected members of the “common set” of H. pylori genes have
allowed the identification of targets for drug discovery in a variety of H. pylori physiological
functions [107, 108]. These targets include proteins involved in cell envelope synthesis/
integrity, cell division, protein synthesis, nucleic acid biosynthesis, gene expression and
regulation, cell metabolism and energetics, as well as proteins encoded by H. pylori genes of
unknown function [109]. Because many essential proteins are enzymes, it is possible to
establish in vitro assays to detect the ability of compounds to interfere with their enzymatic
activity. The selected essential protein target is overproduced in E.coli, purified, and employed
to identify inhibitory compounds by High Throughput Screening [110, 111]. This involves the
automated micro assay screening of the ability of large numbers of compounds (>200, 000) to
inhibit the enzymatic activity of the target protein. Conformed “hits” are then tested for their
ability to selectively kill H.pylori in vitro, and to eradicate H.pylori infection in an animal model.
Lead compounds are subjected to chemical structure-activity relationship studies to improve
antibacterial potency and selectivity, as well as solubility, oral bioavailability, duration of
action and pharmacokinetic properties [101]. Understanding the mechanism of action of a
particular target enzyme or molecular modeling based on three-dimensional crystal structure
of the protein, with or without bound inhibitor(s), can be used to facilitate medicinal chemistry
studies [112, 113]. As lead compounds are identified, the classical medicinal chemistry and
combinatorial chemistry approaches are applied to improve the potency and the desired
microbiological properties, with the ultimate goal of producing compounds suitable for
human trials.
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5.3. Novel drug delivery approaches
One of the reasons for incomplete eradication of H.pylori is probably due to the short residence
time of antimicrobial agents in stomach so that effective antimicrobial concentration cannot be
achieved in the gastric mucus layer or epithelial cell surfaces where H.pylori resides [114-116].
Conventional tablets and capsules are, in general used for eradication therapy but these do
not remain in stomach for prolonged time therefore it is difficult to reach minimum inhibitory
concentration in gastric mucus where H.pylori colonize. To overcome the problem, a new
concept is proposed based on gstroretentive concept (Floating drug delivery systems and
Mucoadhesive drug delivery systems) with site specific drug delivery [117]. It is expected that
the topical delivery of narrow spectrum antibiotic through floating and bioadhesive drug
delivery system may result in complete removal of organism from stomach.
5.4. Floating drug delivery systems (FDDS)
Floating drug delivery systems have a bulk density less than gastric fluids and so remain
buoyant in the stomach without affecting the gastric emptying rate for a prolonged period
of time. The FDDS can be divided into effervescent and non-effervescent systems. Efferves‐
cent floating dosage forms are matrix type systems prepared with the help of  swellable
polymers such as methylcellulose and chitosan and various effervescent compounds, such
as sodium bicarbonate,  tartaric acid,  and citric acid.  They are formulated in such a way
that  when  comes  in  contact  with  the  acidic  gastric  contents,  CO2 is  liberated  and  gets
entrapped in swollen hydrocolloids, which provides buoyancy to the dosage forms. Non-
effervescent floating dosage forms use a gel forming or swellable cellulose type of hydro‐
colloids,  polysaccharides,  and matrix-forming polymers  like  polycarbonate,  polyacrylate,
polymethacrylate,  and  polystyrene  [118].  The  formulation  method  includes  a  simple
approach  of  thoroughly  mixing  the  drug  and  the  gel-forming  hydrocolloid.  After  oral
administration this  dosage form swells  in  contact  with gastric  fluids  and attains  a  bulk
density of < 1. The air entrapped within the swollen matrix imparts buoyancy to the dosage
form.  The so formed swollen gel-like  structure  acts  as  a  reservoir  and allows sustained
release of drug through the gelatinous mass. While the system floats on the gastric contents,
the drug is released slowly at the desired rate from the system. After release of drug, the
residual system is emptied from the stomach. The FDDS greatly improve the pharmacother‐
apy of the stomach through local drug release, leading to high drug concentrations at the
gastric mucosa for eradicating H.pylori from the submucosal tissue of the stomach, making
it possible to treat stomach and duodenal ulcers, and gastritis [119-121].
In our previous study [114] we have developed the floating in situ gelling system of amoxicillin
and evaluated in vivo efficiency in Mongolian gerbil model, the result indicated that the
floating in situ gel has promising potential for eradicating H.pylori infection. In this study the
gelled solution floated in stomach for >20 h, and the in vivo H.pylori clearance efficiency was
10 time more than that of amoxicillin solution in gerbils model.
Yang et al [119] developed a swellable asymmetric triple-layer tablet with floating ability to
prolong the gastric residence time of triple drug regimen (tetracycline, metronidazole, and
clarithromycin) in H.pylori–associated peptic ulcers using hydroxy propyl methyl cellulose
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(HPMC) and poly ethylene oxide (PEO) as the rate-controlling polymeric matrix. The design
of the delivery system was based on the swellable asymmetric triple-layer tablet approach.
Tetracycline and metronidazole were incorporated into the core layer of the triple-layer matrix
for controlled delivery, while bismuth salt was included in one of the outer layers for instant
release. According to the authors, the aim of such a device was to obtain a simple regimen for
a standard triple therapy. Indeed, they obtained in vitro a duration of buoyancy and sustained
release of metronidazole and tetracycline over prolong time of period. The rapid effect of the
device would be due to the rapidly dissolving layer containing the bismuth salt, which
disintegrated within 10–15 min in vitro. However, no in vivo data are available concerning the
floating characteristics of the drug delivery system or its effect against H.pylori.
Umamaheshwari et al (120) developed several drug delivery systems especially designed to
improve efficiency against H.pylori. In all of them, they used an antiurease drug, acetohy‐
droxamic acid (AHA), as an active agent against the bacterium. H. pylori urease hydrolyses
urea present in the gastric juice and extracellular fluid to generate ammonia and bicarbonate,
which effectively neutralize an acidic pH in its environment [121, 122]. Thus, urease inhibitors
hinder the bacterium to protect itself against low pH and avoid thus the problem of treatment
of antibiotic-resistant strains [123].
The same authors developed polycarbonate microballoons by an emulsion (o/w) solvent
evaporation technique. In vitro (i.e. in simulated gastric fluid) 74% to 85% of microballoons
stayed buoyant up to 12 h and exhibited a sustained drug release profile. In vitro and in vivo
growth inhibition studies were performed using cultures of H. pylori and H. pylori-infected
Mongolian gerbils, respectively. Microballoons showed 10 times higher anti-H. pylori activity
compared with AHA solution [124].
Umamaheshwari et al. [125] developed cellulose acetate butyrate coated floating microspheres
of cholestyamine for targeting to H.pylori infection In vitro (drug release, buoyancy) and in
vivo studies (gastric mucoadhesion in the rat stomach) led the authors to conclude that this
drug delivery system possessed both floating and bioadhesive properties, and may be
successful in the treatment of H.pylori. Katayama et al [126] deveolped a susrtained release
liquid preparation of ampicillin using sodium alginate for the treatment of H.pylori infection.
The gastroretentive property of the device was provided by the ability of sodium alginate to
form a firm gel when an acid or di-or trivalent metal ions (Ca2+, Ba2+, Sr2+) were added. The
authors expected the solution to be able to spread out, adhere to the gastric mucosa, and release
the antibiotic continuously (ampicillin). The alginate formulation gelled in stomach and
delivered ampicillin locally in stomach and showed significant anti H.pylori effect in rat model.
5.5. Mucoadhesive drug delivery systems (MDDS)
Bioadhesive drug delivery systems are used to localize a delivery device within the lumen to
enhance the drug absorption in a site-specific manner. Mucoadhesive drug carrier may
prolong the residence time of drug in stomach because they adhere to mucus surface, resulting
in an effective localizing drug concentration. Mucoadhesion is a very complex process and
several theories have been put forward to explain the mechanism, including electrical,
adsorption, and wetting and diffusion theories [127]. Because the mucosal surface is negatively
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charged, a positive charge on polymer might facilitate the mucoadhesion process. Some of the
most promising charged excipients used commonly in these systems include polycarbophil,
carbopol, lecithins, chitosan, carboxy methyl cellulose and gliadin, etc. Some investigators
have tried a synergistic approach between floating and bioadhesion systems [120, 124, 128].
Among the mucoadhesive formulation, mucioadhesive microspheres have gained considera‐
ble attention due to their ability to adhere to mucus layer as well as release drugs locally at the
infected cell line.
Nagahara et al [128] formulated mucoadhesive microspheres containing amoxicillin. They
dispersed the drug and bioadhesive polymers (carboxyvinyl polymer and curdlan [polysac‐
charide]) in melted hydrogenated castor oil. They compared these microspheres with an
amoxicillin suspension in infected Mongolian gerbils under feeding conditions. The micro‐
spheres with an amoxicillin dose of 1.0 mg/kg provided the same clearance rate (20%) as the
amoxicillin suspension with a dose of 10 mg/kg. This means that the amoxicillin-microspheres
provided 10 times greater anti-H.pylori activity than the amoxicillin suspension. Moreover,
adhesion of microspheres on the stomach wall was observed (°47% and °20% remained in the
stomach after 2 and 4 h, respectively). The authors concluded that these mucoadhesive
microspheres containing an appropriate antimicrobial agent should be useful for the eradica‐
tion of H. pylori.
Wang et al. [129] studied positively charged gelatin microspheres as gastric mucoadhesive
drug delivery system for eradication of H.pylori. Umamaheshwari et.al [130] developed
nonoparticles bearing amoxicillin using gliadin polymer rand evaluated in-vivo the anti
H.pylori efficiency of nanoparicles in gerbil model, results were found to be promising molecule
to eradicate of H.pylori infection. Radiet et.al [131] developed tetracycline-loaded crosslinked
chitosan microspheres to increase the local concentration of the antibiotic in the stomach and,
thus eradicate H.pylori infection. The microspheres were examined for gastric residence time
and local tetracycline concentrations in fasted gerbils. The microspheres were found to reside
in the stomach even after 10 h of administration.
Recently, Zhepeng et.al [132] also published a study on mucoadhesive microspheres contain‐
ing amoxicillin by an emulsification/evaporation method, using ethylcellulose as matrix and
carbopol 934P as a mucoadhesive polymer. This work showed that free amoxicillin was rapidly
degraded in acidic medium; however, amoxicillin entrapped in the microspheres micro‐
spheres kept stable. Furthermore, studies on the in vivo clearance of H.pylori revealed that, in
a single-dosage administration, the mucoadhesive microspheres had a better effectiveness
than that of amoxicillin powder.Finally this study showed a complete eradication of H.pylori
with microspheres in five of six rat stomachs, whereas amoxicillin powder showed four times
less effectiveness. The authors found a tendency for an effective anti-H.pylori activity induced
by mucoadhesive microspheres, but concluded that larger groups of animal are required to
confirm these results.
Among all the drug delivery approaches (Dosage forms) described herein, some provide
interesting solutions, although many of them present drawbacks. In the particular case of
H.pylori eradication, the ideal dosage form should, to be really effective, not only stay in the
stomach, but also target the bacterium. However, knowledge about this pathogen discovered
twenty years ago is still poor. More data are necessary, for example, to identify an ‘‘ubiquitous’’
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receptor (i.e. for all H.pylori strains) at the surface of the bacterium, which could provide a
strong interaction with a ligand [133-135]. Thus, the development of an efficient gastroretentive
dosage form against H. pylori is closely linked to a better understanding of its pathogenicity
mechanisms.
6. Conclusion
Considerable advances have been made in understanding the evolution of the organism and
pathogenesis of disease. Although combination therapies have high rates of eradication, the
preferred therapy would be one which use a low dose of a single drug with a short duration
treatment and without any adverse effect. The sequencing of two strains of H.pylori has
provided a wealth of data that will be useful in understanding the pathogenesis of disease,
microbial evolution and highlight potential therapeutic targets and potential vaccine candi‐
dates. In future, it is likely to advance understanding of disease progression and aid in the
development of novel therapies. First aspect of research is that genomic studies are arousing
considerable interest, and will certainly be followed up in future research for development of
new therapies. A second area of research that is becoming increasingly important is the
development of novel targeted drug delivery systems for H.pylori infection. The floating and
mucoadhesive formulation of antibacterial drugs have shown good H. pylori clarence effect in
both in-vitro and in-vivo animal model studies. However, extensive clinical studies are
required in human to establish a correlation.
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